Good morning :)
Place Order
Add to Watchlist

Syngene International Ltd

SYNGENE Share Price

644.200.60% (+3.85)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹25,881 cr, stock is ranked 292

Stock is 2.18x as volatile as Nifty

SYNGENE Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹25,881 cr, stock is ranked 292

Stock is 2.18x as volatile as Nifty

SYNGENE Performance & Key Metrics

SYNGENE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
52.165.480.19%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.156.590.82%

SYNGENE Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
71%
Analysts have suggested that investors can buy this stock

from 7 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

SYNGENE Company Profile

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.

Investor Presentation

View older View older 

Mar 12, 2025

PDF
View Older Presentations

SYNGENE Similar Stocks (Peers)

Compare with peers Compare with peers 

SYNGENE Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
83.68
83.68
1Y Return
51.99%
51.99%
Buy Reco %
47.83
47.83
PE Ratio
29.96
29.96
1Y Return
46.35%
46.35%
Buy Reco %
0.00
0.00
PE Ratio
1,269.75
1,269.75
1Y Return
52.35%
52.35%
Buy Reco %
0.00
0.00
PE Ratio
31.15
31.15
1Y Return
81.09%
81.09%
Buy Reco %
0.00
0.00
PE Ratio
-40.59
-40.59
1Y Return
59.20%
59.20%
Buy Reco %
0.00
0.00
Compare with Peers

SYNGENE Forecast

SYNGENE Forecasts

Price

Revenue

Earnings

SYNGENE

SYNGENE

Income

Balance Sheet

Cash Flow

SYNGENE Income Statement

SYNGENE Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.59%, vs industry avg of 7.5%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 17.77% to 18.88%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 3.78%, vs industry avg of 8.25%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue1,484.901,900.702,164.802,283.902,657.003,263.803,579.203,746.203,746.20
Raw Materialssubtract395.20505.30518.60551.70770.60902.20873.60925.402,600.60
Power & Fuel Costsubtract34.7041.3045.8057.4064.8069.2069.7069.00
Employee Costsubtract379.60472.70580.40660.20718.10841.70888.70983.90
Selling & Administrative Expensessubtract116.20123.10123.80107.80137.60196.70249.00272.80
Operating & Other expensessubtract32.60146.40125.40135.40147.70248.70404.30349.50
Depreciation/Amortizationsubtract131.40164.20219.30274.50309.70366.50425.90432.60432.60
Interest & Other Itemssubtract22.7032.3034.6027.7024.1045.2047.2053.1053.10
Taxes & Other Itemssubtract67.1083.80104.8064.3088.60129.20110.80163.70163.70
EPS7.638.2910.3010.129.8911.5812.7012.3312.33
DPS0.500.250.000.001.001.251.251.251.25
Payout ratio0.070.030.000.000.100.110.100.100.10

SYNGENE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF

Investor Presentation

Mar 12PDF
Jan 23PDF
Oct 23PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Jul 26PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Apr 26PDF
Jan 23PDF
Oct 19PDF
Jul 20PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Apr 27PDF
Jan 19PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

SYNGENE Stock Peers

SYNGENE Past Performance & Peer Comparison

SYNGENE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Syngene International Ltd52.165.480.19%
Divi's Laboratories Ltd83.6813.510.43%
Aarti Pharmalabs Ltd29.964.640.56%
Dishman Carbogen Amcis Ltd1,269.750.73

SYNGENE Stock Price Comparison

Compare SYNGENE with any stock or ETF
Compare SYNGENE with any stock or ETF
SYNGENE
Loading...

SYNGENE Holdings

SYNGENE Shareholdings

SYNGENE Promoter Holdings Trend

SYNGENE Promoter Holdings Trend

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.99%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SYNGENE Institutional Holdings Trend

SYNGENE Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.17%

Tickertape Separator

SYNGENE Shareholding Pattern

SYNGENE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding52.74%17.86%3.64%19.47%6.29%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

SYNGENE Shareholding History

SYNGENE Shareholding History

Dec '23MarJunSepDec '24Mar21.20%20.92%20.63%20.72%20.64%19.47%

Mutual Funds Invested in SYNGENE

Mutual Funds Invested in SYNGENE

No mutual funds holding trends are available

Top 5 Mutual Funds holding Syngene International Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.2450%2.47%0.12%21/51 (0)
0.2227%2.55%-0.70%38/68 (-2)
0.1026%1.76%-0.38%18/89 (-8)

Compare 3-month MF holding change on Screener

SYNGENE Insider Trades & Bulk Stock Deals

SYNGENE Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SYNGENE stock

smallcases containing SYNGENE stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Syngene International Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

SYNGENE's Wtg.
9.57%
9.57%
CAGR
20.54%

SYNGENE Events

SYNGENE Events

SYNGENE Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

SYNGENE Dividend Trend

No dividend trend available

SYNGENE Upcoming Dividends

SYNGENE Upcoming Dividends

No upcoming dividends are available

SYNGENE Past Dividends

SYNGENE Past Dividends

Cash Dividend

Ex DateEx DateJun 27, 2025

Final
Final | Div/Share: ₹1.25

Dividend/Share

1.25

Ex DateEx Date

Jun 27, 2025

Cash Dividend

Ex DateEx DateJun 28, 2024

Final
Final | Div/Share: ₹1.25

Dividend/Share

1.25

Ex DateEx Date

Jun 28, 2024

Cash Dividend

Ex DateEx DateJun 30, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jun 30, 2023

Cash Dividend

Ex DateEx DateJun 30, 2023

Special
Special | Div/Share: ₹0.75

Dividend/Share

0.75

Ex DateEx Date

Jun 30, 2023

Cash Dividend

Ex DateEx DateJun 30, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jun 30, 2022

SYNGENE Stock News & Opinions

SYNGENE Stock News & Opinions

Spotlight
Syngene's Bengaluru-based facility gets 'NAi' status from US FDA

The inspection concluded successfully, with the facility found to be in compliance with the required regulations. The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as 'no action indicated' (NAI). 'The company remains commitment to high operating standards and rigorous compliance with global regulatory requirements across all its operations,' Syngene said in a statement. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. The scrip had lost 1.57% to end at Rs 652.50 on the BSE on Friday. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Syngene slides on tepid results and toned-down forecast

On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. Reported EBITDA rose 9% year-on-year to Rs 363 crore in Q4 March 2025. EBITDA margin (%) stood at 35% in Q4FY25, lower than 35.7% in Q4FY24. For the full year, net profit declined 2.71% to Rs 496.20 crore while net sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 over the year ended March 2024. Reported EBITDA rose 1% year-on-year to Rs 1,114 crore in FY25. EBITDA margin (%) stood at 30% in FY25, lower than 30.9% in FY24. In its outlook for FY26, the Syngene management anticipates the reported revenue growth will likely be in the mid-single digits. They also foresee the EBITDA margin moderating from current levels to the mid-twenties and a year-on-year decline in profit after tax. Commenting on the results, Peter Bains, managing director and CEO, Syngene International, said, Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit. Deepak Jain, chief financial officer, Syngene International, said, Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax. The company's board recommended a final dividend of Re 1.25 per equity share for the financial year 2024-25. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Syngene International Ltd leads losers in 'A' group

Nava Ltd, 360 ONE WAM Ltd, KFin Technologies Ltd and Can Fin Homes Ltd are among the other losers in the BSE's 'A' group today, 24 April 2025.Syngene International Ltd lost 13.07% to Rs 652 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 6.27 lakh shares were traded on the counter so far as against the average daily volumes of 16486 shares in the past one month.Nava Ltd tumbled 4.70% to Rs 470.05. The stock was the second biggest loser in 'A' group.On the BSE, 37641 shares were traded on the counter so far as against the average daily volumes of 34596 shares in the past one month.360 ONE WAM Ltd crashed 4.30% to Rs 1015.75. The stock was the third biggest loser in 'A' group.On the BSE, 62266 shares were traded on the counter so far as against the average daily volumes of 68845 shares in the past one month.KFin Technologies Ltd fell 4.26% to Rs 1231.55. The stock was the fourth biggest loser in 'A' group.On the BSE, 73027 shares were traded on the counter so far as against the average daily volumes of 1.36 lakh shares in the past one month.Can Fin Homes Ltd plummeted 4.26% to Rs 713. The stock was the fifth biggest loser in 'A' group.On the BSE, 39072 shares were traded on the counter so far as against the average daily volumes of 20594 shares in the past one month.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Volumes spurt at Syngene International Ltd counter

Natco Pharma Ltd, Newgen Software Technologies Ltd, MMTC Ltd, Glaxosmithkline Pharmaceuticals Ltd are among the other stocks to see a surge in volumes on NSE today, 24 April 2025.Syngene International Ltd registered volume of 168.31 lakh shares by 14:14 IST on NSE, a 34.31 fold spurt over two-week average daily volume of 4.91 lakh shares. The stock slipped 12.51% to Rs.655.45. Volumes stood at 6.35 lakh shares in the last session.Natco Pharma Ltd clocked volume of 144.27 lakh shares by 14:14 IST on NSE, a 34.05 times surge over two-week average daily volume of 4.24 lakh shares. The stock gained 8.94% to Rs.920.00. Volumes stood at 3.69 lakh shares in the last session.Newgen Software Technologies Ltd saw volume of 117.97 lakh shares by 14:14 IST on NSE, a 28.87 fold spurt over two-week average daily volume of 4.09 lakh shares. The stock increased 13.03% to Rs.1,122.60. Volumes stood at 14 lakh shares in the last session.MMTC Ltd registered volume of 410.32 lakh shares by 14:14 IST on NSE, a 26.01 fold spurt over two-week average daily volume of 15.78 lakh shares. The stock rose 14.15% to Rs.63.73. Volumes stood at 14.89 lakh shares in the last session.Glaxosmithkline Pharmaceuticals Ltd recorded volume of 17.98 lakh shares by 14:14 IST on NSE, a 14.9 times surge over two-week average daily volume of 1.21 lakh shares. The stock gained 3.19% to Rs.2,937.50. Volumes stood at 85241 shares in the last session.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Syngene International to conduct AGM

Syngene International announced that the 32nd Annual General Meeting(AGM) of the company will be held on 23 July 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Board of Syngene International recommends final dividend

Syngene International announced that the Board of Directors of the Company at its meeting held on 23 April 2025, inter alia, have recommended the final dividend of Rs 1.25 per equity Share (i.e. 12.5%) , subject to the approval of the shareholders.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Syngene International consolidated net profit declines 2.81% in the March 2025 quarter

Net profit of Syngene International declined 2.81% to Rs 183.30 crore in the quarter ended March 2025 as against Rs 188.60 crore during the previous quarter ended March 2024. Sales rose 11.03% to Rs 1018.00 crore in the quarter ended March 2025 as against Rs 916.90 crore during the previous quarter ended March 2024. For the full year,net profit declined 2.71% to Rs 496.20 crore in the year ended March 2025 as against Rs 510.00 crore during the previous year ended March 2024. Sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 as against Rs 3488.60 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1018.00916.90 11 3642.403488.60 4 OPM %33.7534.56 -28.6029.08 - PBDT346.60320.10 8 1060.501057.80 0 PBT240.50209.00 15 627.90631.90 -1 NP183.30188.60 -3 496.20510.00 -3 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Syngene International fixes record date for final dividend

Syngene International has fixed 27 June 2025 as record date for payment of final dividend of Re.1.25/- per equity share of Rs. 10/- for the financial year 2024-25. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Syngene International schedules board meeting

Syngene International will hold a meeting of the Board of Directors of the Company on 23 April 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Syngene International appoints Peter Bains as MD & CFO

Peter Bains, with over 30 years of global experience in biopharmaceuticals, was appointed group CEO of Biocon in September 2023. Holding a bachelor's degree in science from the University of Sheffield, Bains previously served as CEO of Syngene International, where he led its public listing in 2015. He has also held leadership roles at Sosei Group and GlaxoSmithKline. Bains rejoined Biocon as an independent director in December 2022 before being appointed CEO. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company reported a 17.58% increase in consolidated net profit to Rs 131.1 crore in Q3 FY25 as compared with Rs 111.5 crore in Q3 FY24. Revenue from operations jumped 10.57% YoY to Rs 943.7 crore in Q3 FY25. Shares of Syngene International rose 0.95% to Rs 725 on the BSE.Powered by Capital Market - Live

3 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Syngene International Ltd (SYNGENE) today?

    The share price of SYNGENE as on 4th July 2025 is ₹644.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Syngene International Ltd (SYNGENE) share?

    The past returns of Syngene International Ltd (SYNGENE) share are
    • Past 1 week: -1.33%
    • Past 1 month: -0.26%
    • Past 3 months: -11.10%
    • Past 6 months: -25.28%
    • Past 1 year: -11.24%
    • Past 3 years: 15.68%
    • Past 5 years: 47.68%

  3. What are the peers or stocks similar to Syngene International Ltd (SYNGENE)?
  4. What is the dividend yield % of Syngene International Ltd (SYNGENE) share?

    The current dividend yield of Syngene International Ltd (SYNGENE) is 0.19.

  5. What is the market cap of Syngene International Ltd (SYNGENE) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Syngene International Ltd (SYNGENE) is ₹25881.88 Cr as of 4th July 2025.

  6. What is the 52 week high and low of Syngene International Ltd (SYNGENE) share?

    The 52-week high of Syngene International Ltd (SYNGENE) is ₹960.60 and the 52-week low is ₹599.55.

  7. What is the PE and PB ratio of Syngene International Ltd (SYNGENE) stock?

    The P/E (price-to-earnings) ratio of Syngene International Ltd (SYNGENE) is 52.16. The P/B (price-to-book) ratio is 5.48.

  8. Which sector does Syngene International Ltd (SYNGENE) belong to?

    Syngene International Ltd (SYNGENE) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

  9. How to buy Syngene International Ltd (SYNGENE) shares?

    You can directly buy Syngene International Ltd (SYNGENE) shares on Tickertape. Simply sign up, connect your demat account and place your order.